Drugs / Detox-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00007969 | Oct 2000 → ? | cutaneous melanoma | QLT Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00019006 Background | Mar 1995 → ? | malignant colon neoplasm, non-small cell lung carcinoma, pancreas disorder, rectal carcinoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00003638 Background | Jan 1999 → Jan 2007 | breast cancer | Oncothyreon Canada Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Detox-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00007969 ↗ |
| Route | Subcutaneous | “Patients receive tumor-specific mutated ras peptide combined with Detox-B adjuvant subcutaneously monthly for 3 months.” NCT00019006 ↗ |